Proxy Votes Now

Home › Funds › Fidelity › Select Pharmaceuticals Portfolio

Select Pharmaceuticals Portfolio (FPHAX) proxy voting record 2025-2026

Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007481

Ticker: FPHAX (C000020455)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 355 with, 9 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 9 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Fidelity as a whole

The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFidelityItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)95.1%32994.1%974,562
Backed environmental and social shareholder proposals at US companiesn/a66.8%11,096

Where this fund voted differently from most Fidelity funds

Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Fidelity funds on 13 items (3.6% of the 359 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Corcept Therapeutics Incorporated2026-05-21To approve an amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan to increase the number of shares available thereunder and clarify certain other language in the plan.AgainstFOR — 20 of 25 Fidelity fundsAgainstApproved, 69.0% support
Corcept Therapeutics Incorporated2026-05-21Election of Directors: David L. MahoneyForWITHHOLD — 19 of 24 Fidelity fundsForElected, 66.1% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Laura BregeWithholdFOR — 14 of 17 Fidelity fundsAgainstElected, 95.8% support
Ionis Pharmaceuticals, Inc.2026-06-04To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.AgainstFOR — 25 of 34 Fidelity fundsAgainstApproved, 77.0% support
Definium Therapeutics, Inc.2026-06-11To consider, and if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares.AgainstFOR — 15 of 19 Fidelity fundsAgainstApproved, 92.5% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 70.3% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 65.0% support
Capricor Therapeutics, Inc.2026-06-04ELECTION OF DIRECTORS: Frank LitvackWithholdFOR — 13 of 17 Fidelity fundsAgainstPassed (calculated), 68.6% support
Edgewise Therapeutics, Inc.2026-06-04Conduct an advisory vote on the compensation of our named executive officers.AgainstFOR — 14 of 19 Fidelity fundsAgainstApproved, 96.1% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Hongbo LuAgainstFOR — 14 of 22 Fidelity fundsAgainst—
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: William WaddillAgainstFOR — 14 of 22 Fidelity fundsAgainstPassed (calculated), 90.3% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Michael S. PerryAgainstFOR — 13 of 22 Fidelity fundsAgainst—
uniQure N.V.2026-06-10Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime.ForAGAINST — 10 of 16 Fidelity fundsForApproved, 74.5% support

Download all 13 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 69.8% of this fund’s 364 such votes could be given a sector; the other 110 (30.2%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care25493.5%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2000
Audit-related440
Capital Structure360
Say-on-Pay340
Corporate Governance233
Compensation190
Other Social Issues53
Environment or Climate33
Shareholder Rights and Defenses30
Extraordinary Transactions10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$520M102
Johnson & JohnsonApril 23, 2026$134M151
Moderna, Inc.November 12, 2025$100M20
Merck & Co., Inc.May 26, 2026$85M183
Gilead Sciences, Inc.April 30, 2026$79M153
Elanco Animal Health IncorporatedMay 21, 2026$66M70
Moderna, Inc.May 6, 2026$52M50
Viatris Inc.May 15, 2026$36M150

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor

Search this fund’s votes by company

369 ballot items at 41 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Select Pharmaceuticals Portfolio (FPHAX) voted at 41 shareholder meetings of 39 companies, on 369 ballot items in all. Where management made a recommendation, the fund followed it on 97.5% of the items and voted against it 9 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 9 shareholder proposals. It voted FOR the board's own proposals more often than Fidelity's funds as a whole (95.1% against 94.1%). It voted differently from most Fidelity funds on 13 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.